Table 4.
Specific research objectives | |||||||
---|---|---|---|---|---|---|---|
Data collection | SO1 Access to care, retention, and healthcare pathways |
SO2 Clinical, behavioral, and social evolution |
SO3 Initiation, practices, and compliance with PrEP |
SO4 Comparison of HIV care (PRINCESSE vs. current) |
SO5 Prevention and care of hepatitis B | SO6 Unintended consequences of the PRINCESSE intervention |
SO7 Vaginal microbiota, HPV infection types, and antimicrobial STI resistance |
PRINCESSE cohort | |||||||
P1. Clinical and safety data | X | X | X | X | X | X | |
P2. Socio-behavioral questionnaires | X | X | X | X | X | ||
P3. Biological data | X | X | X | X | X | ||
P4. In-depth interviews with participants | X | X | X | ||||
Additional data collection | |||||||
A1. Medical and activity records of Aprosam (PRINCESSE participants) | X | ||||||
A2. Medical records of HIV+ FSW patients (not participating in the PRINCESSE cohort) | X | ||||||
A3. In-depth interviews with members and key informants of the FSW community | X | X | |||||
A4. In-depth interviews with PRINCESSE follow-up actors | X | X | X |